$SPRB 18x normal volume. IPOd at 15$ a share on 10/9/2020. Late stage clinical trials. Oppenheimer appears to have optimism that it will get approved. No reason why it fell so hard. Hit a high of 35$ back in November of 2020. 15$ price target from Oppenheimer (5.4x) from current price).$Pfizer(PFE)$